Emcure Pharmaceuticals Ltd.

Pune, India

Emcure Pharmaceuticals Ltd.

Pune, India

Time filter

Source Type

— The global folate market has seen a positive growth in the global market particularly in Asia-Pacific. The major factors augmenting the market is rising awareness about health. Owing to this factor, the consumption rate has increased on a higher rate. Along with this, folate or folic acid is very much helpful in pregnancy which helps in preventing defects at the time of birth. Study Objectives of Folate Market • To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Global Folate Market • To provide insights about factors affecting the market growth • To Analyse the Global Folate Market based on various factors- price analysis, supply chain analysis, porter’s five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World (ROW) • To provide country-level analysis of the market with respect to the current market size and future prospective • To provide country-level analysis of the market for segment by applications and regions • To provide strategic profiling of key players in the market, comprehensively analysing their core competencies, and drawing a competitive landscape for the market • To track and analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Folate Market Key Players The leading market players in the global folate market mainly include • Zydus Cadila • Medicamen Biotech • Emcure Pharmaceuticals • Synokem Pharmaceuticals • Jiangxi Tianxin Pharmaceutical • Anhui Shengda Pharmaceutical • D.S. Lab The reports also covers brief analysis of Geographical Region includes: North America • US • Canada • Mexico • Latin America Europe The market report for Folate of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions. For more information, please visit https://www.marketresearchfuture.com/reports/folate-market-1091


Patent
EMCURE PHARMACEUTICALS Ltd | Date: 2012-08-27

The present invention provides a convenient and industrially viable process for preparation of Zolmitriptan (I) having desired purity. The invention specifically relates to a method for isolating (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride (IIIa) of desired purity by separating the undesired inorganic side products such as stannous hydroxide by manipulation of pH at different stages and finally treating with N,N-dimethylamino butyraldehyde diethyl acetal in an acidic medium to provide Zolmitriptan (I) conforming to regulatory specifications.


Patent
EMCURE PHARMACEUTICALS Ltd | Date: 2012-09-05

Controlled release oral dosage formulations containing calcium channel blocker and processes for preparation thereof, are provided for once a day treatment. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. In one embodiment, the formulation provides controlled release of micronized nisoldipine with one or more pH independent release controlling polymers. The controlled release matrix formulation is advantageous and can be prepared by a simple, economically viable process as compared to complex core-coat prior-art versions.


Patent
Emcure Pharmaceuticals Ltd | Date: 2012-12-21

The present invention relates to a novel synthetic route for the preparation of raltegravir and pharmaceutically acceptable salts, starting from 2-amino-2-methylpropanenitrile and oxadiazole carbonyl chloride, through the formation of a pyrimidinone intermediate of formula (V).


Patent
Emcure Pharmaceuticals Ltd | Date: 2011-06-08

The present invention provides a simple method for synthesis of taxane derivatives such as paclitaxel docetaxel or cabazitaxel. Taxane derivative obtained by present process posses significant stability and formation of 7-epimer, which is a principal degradation product, is significantly reduced. The taxane derivatives obtained by present process are highly useful for preparing the pharmaceutical compositions.


The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R_(1), R_(2 )and R_(3 )are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R_(1 )is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R_(2 )is methyl, methoxy and hydrogen, and R_(3 )is methyl and hydrogen.


Patent
Emcure Pharmaceuticals Ltd | Date: 2012-04-09

Disclosed is process for the preparation of a key Rilpivirine intermediate namely, (E)-4-(2-cyanoethenyl)-2,6-dimethylphenylamine hydrochloride (II) by a process comprising reaction of the tetrafluoroborate salt of the diazonium ion of 2,6-dimethyl-4-amino-1-carboxybenzyl phenylamine (VI) with acrylonitrile in presence of palladium acetate, followed by treatment with an acid and its subsequent conversion to the hydrochloride salt (II), wherein the undesired Z isomer is less than 0.5% and provides Rilpivirine hydrochloride having Z isomer less than 0.1%.


Patent
EMCURE PHARMACEUTICALS Ltd | Date: 2014-11-14

A process for preparation of diethyl 2-aetamido-2-(4-octyl phenyl)ethyl malonate (III), a key intermediate of fingolimod hydrochloride comprising reaction of 2-(4-octylphenyl)ethyl iodide (IV) with diethyl acetamido malonate in presence of a base and an iodinating agent and in an organic solvent. The compound of formula (III) thus obtained provided fingolimod hydrochloride (Ia) having associated impurities below the regulatory limits.


The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R_(1), R_(2 )and R_(3 )are independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. R_(1 )is methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, R_(2 )is methyl, methoxy and hydrogen, and R_(3 )is methyl and hydrogen.


Patent
Emcure Pharmaceuticals Ltd | Date: 2016-06-28

The present invention relates to a novel synthetic route for the preparation of raltegravir and pharmaceutically acceptable salts, starting from 2-amino-2-methylpropanenitrile and oxadiazole carbonyl chloride, through the formation of a pyrimidinone intermediate of formula (V).

Loading Emcure Pharmaceuticals Ltd. collaborators
Loading Emcure Pharmaceuticals Ltd. collaborators